Cargando…
2382. Ceftolozane/Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections in Immunocompromised Patients: A Multi-Center Study
BACKGROUND: Ceftolozane/tazobactam (TOL-TAZ) is a novel cephalosporin antibiotic combined with a known β-lactamase inhibitor. It has activity against some extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and multidrug-resistant Pseudomonas aeruginosa (MDRPA). To date, little experie...
Autores principales: | Elabor, Abdulrahman, Molnar, Esther, King, Madeline, Gallagher, Jason |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255387/ http://dx.doi.org/10.1093/ofid/ofy210.2035 |
Ejemplares similares
-
2435. Clinical Outcomes With Ceftolozane–Tazobactam in Patients With Multidrug-Resistant (MDR) Pseudomonas aeruginosa Bloodstream Infections: A Multi-Center Study
por: King, Madeline, et al.
Publicado: (2018) -
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
por: Gallagher, Jason C, et al.
Publicado: (2018) -
A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections
por: Hart, Delaney E, et al.
Publicado: (2021) -
Ceftolozane-tazobactam for the Treatment of Multi Drug-resistant Pseudomonas aeruginosa (MDRPA) Infections
por: Molnar, Esther, et al.
Publicado: (2017) -
2281. Ceftolozane–tazobactam (C/T) Treatment Outcomes in Immunocompromised (IC) Patients with Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PA) Infections
por: Hart, Delaney E, et al.
Publicado: (2019)